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Triple negative breast cancer is an aggressive form of breast cancer with limited treatment options and is without proven
targeted therapy. Understanding the molecular basis of triple negative breast cancer is crucial for eﬀective new drug development.
Recent genomewide gene expression and DNA sequencing studies indicate that this cancer type is composed of a molecularly
heterogeneous group of diseases that carry multiple somatic mutations and genomic structural changes. These ﬁndings have
implications for therapeutic target identiﬁcation and the design of future clinical trials for this aggressive group of breast cancer.
1.Introduction
Triple negative breast cancer (TNBC) is deﬁned by the
absence of estrogen receptor (ER), progesterone receptor
(PR), and HER-2 Overexpression. It accounts for 15–20% of
all breast cancer cases [1, 2] ,b u to c c u r sa tah i g h e rf r e q u e n c y
inyoungpremenopausalwomenwithAfricanAncestry(AA)
[3]. High body mass index (BMI) and high parity, instead
of low parity in other types of breast cancer, have been
associated with increased risk for TNBC [4–6]. TNBC is
associated with an overall poor prognosis as exempliﬁed by a
higherrateofearlyrecurrenceanddistantmetastasistobrain
and lungs compared to other breast cancer subtypes [7, 8].
The unfavorable clinical outcome is partly explained by its
aggressive pathologic features including a higher histology
grade and mitotic index [9].
Chemotherapy is the only systemic therapy currently
available for TNBC and is curative in a subset of patients
with chemotherapy-sensitive disease. A higher rate of patho-
logic complete response (pCR) to standard chemotherapy
has been observed in patients with TNBC compared to
ER+ disease. A pCR rate of 22% in TNBC versus 11%
in ER+ disease was reported in a study of over 1000
patients treated with neoadjuvant anthracycline and taxane-
based chemotherapy regimens [10]. The excellent outcome
associated with the pCR, however, is in contrast to the high
risk of recurrence and cancer-related deaths in those with
residuedisease.Althoughalternativeagentssuchasplatinum
compounds have demonstrated promising activity, up to 70–
80% of patients have residual cancer following neoadjuvant
cisplatin [11]. In the metastatic setting, TNBC is typically
associated with an initially higher response rate, but in a
shortertimetoprogressionfollowingtreatmentwithexisting
chemotherapy agents, resulting a shorter overall survival
compared to ER+ breast cancer in multiple studies [12].
The underlying molecular mechanism for this paradox is yet
to be elucidated, although one could hypothesize that the
inherent genomic instability of TNBC renders the possibility
ofafasteradaptation tothecytotoxic eﬀectofchemotherapy.
The treatment options for chemotherapy-resistant
TNBC are limited. The established targeted therapies,
including endocrine treatment and HER2-targeted agents,
are ineﬀective. Although several small molecule inhibitors
and monoclonal antibodies against important cellular
pathways have been tested in clinical trials, none has
entered clinical practice due to limited eﬃcacy. A better
understanding of the underlying biology of TNBC is
therefore needed to identify new therapeutic targets and
to pinpoint which TNBC patients may beneﬁt from them.
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technologies have made it possible to analyze the tumor at
the genomic level for therapeutic target discovery. These
studies indicate that TNBC is a molecularly heterogeneous
group of diseases with highly complex genomic aberrations.
A further classiﬁcation at the molecular level may be
possible to facilitate drug development. In this paper, we
will examine recent publications on the molecular basis of
TNBC, with a particular focus on genomewide studies and
their implication for future clinical trials.
2. Molecular Subclassiﬁcationof
TNBC Based onGeneExpressionProﬁling
In the seminal paper by Sørlie et al. breast cancer was
subdivided into ﬁve intrinsic molecular subtypes, including
luminal A, luminal B, HER-2 enriched, normallike, and
basallike, based on hierarchical clustering analysis of approx-
imately 500 genes (termed the intrinsic gene set because
expression was not modulated by treatment) on a cDNA
microarray study of 65 breast tumors obtained from 42
diﬀerent individuals (Table 1)[ 8]. The term luminal A and
luminal B subtypes was coined to reﬂect the presumed
luminal epithelial cells origin of these cancers because of
similarities in gene expression pattern and the expression
of ER [13]. In contrast, HER-2-enriched subtype has high
expression of HER-2 and genes that are close to HER-
2 in the genome such as GRB7, but low expression of
luminal and hormone receptor-related genes. Some of the
clinicalHER-2-positivecancersactuallydonotfallintoHER-
2-enriched subtype but belong to the luminal categories
because of the coexpression of ER. These tumors are likely
biologically diﬀerent from those of the HER-2-enriched
intrinsic subtype. Normal-like subtypes have, as their name
implies, similar expression pattern to normal breast tissue.
The signiﬁcance of this subtype has yet to be determined,
and some argue that it may represent a mere contamination
of samples with normal breast tissue. The intrinsic subtypes
carry prognostic signiﬁcance with the basal-like subtype
having the worse clinical outcome. The recent development
of the 50-gene subtype predictor (PAM50), a RT-PCR assay
that assigns intrinsic subtypes using RNA from formalin
ﬁxed and paraﬃn embedded tissue, has created a possible
gold standard intrinsic subtype test for clinical application
[14]. Although all intrinsic subtypes have been identiﬁed in
TNBC, basal-like subtype is the most common, followed by
the recently identiﬁed Claudin-low subtype [15].
2.1. Basal-Like Subtype. TNBC is most commonly associated
withbasal-likeintrinsicsubtype.Basal-likesubtypeistermed
after the basal epithelial layer cells due to their similarities
in gene expression pattern. Basal-like breast cancers typically
express basal cytokeratins such as CK5/6, CK17 as well as
cadherin, and epidermal growth factor receptor (EGFR)
[16].Theyarealsofrequentlytriplenegative(negativeforER,
PR, and HER2). In one study, about 70% of TNBC belonged
to basal-like subtype, and 76% of basal-like cancers were
f o u n dt ob et r i p l en e g a t i v e[ 1]. Many studies have used the
two interchangeably, however, and it is important to note
Table 1: Intrinsic subtypes of breast cancer.
Intrinsic subtypes
of breast cancer Characteristics
Luminal A
High level expression of ER and ER-associated
genes, associated with a favorable clinical
outcome.
Luminal B
Low level expression of ER and ER-associated
genes, associated with a higher tumor cell
proliferation rate and a worse clinical outcome
compared to the luminal A subtype.
HER-2 Enriched
High level expression of HER2 and GRB7,
associated with a poor outcome before the era
of HER2-targeted agents.
Basal-like
Positive for the expression of basal cytokeratin
but negative for the expression of luminal- and
HER2-related genes, associated with a high
tumorcellproliferationrateandapoorclinical
outcome.
Normal-like
Similar expression compared to normal breast,
suspicious for normal cell contamination.
Claudin-low
Lack the expression of claudin proteins that
are implicated in cell-cell adhesion, but high
expression of EMT and putative stem cell
markers, associated with ER and HER2 nega-
tivity but low in basal cytokeratin expression.
that although there is signiﬁcant overlap, basal-like subtype
does not encompass all of TNBC and may itself be another
too broad of a classiﬁcation.
An association has been described between the basal-like
subtype and BRCA1-gene-related breast cancers. The major-
ity of BRCA1-related tumors are basallike by microarray
analysis [12, 17], and sporadic basal-like breast cancers have
been associated with “BRCAness,” which is characterized by
high tumor grade, lymphocytic inﬁltrate, pushing margins,
ERandHER2negativity,associationwithTP53mutations,c-
myc ampliﬁcation, and multiple chromosome abnormalities
including X-chromosome isodisomy [18]. Although somatic
mutations in BRCA1/2 rarely occur in sporadic breast cancer
[19–21], a rather high incidence, approaching 20%, of germ-
line mutations in BRCA1 or 2 has been reported in patients
with TNBC [21]. In a study of 77 cases of sporadic TNBC
from MD Anderson, BRCA1 mutation was identiﬁed in
12 (15.6%) (only one somatic) and BRCA2 mutation was
i d e n t i ﬁ e di n3( 3 . 9 % )[ 21]. More commonly, loss of BRCA
expression due to gene silencing by promoter methylation
has been shown in TNBCs [22]. It has been demonstrated
that BRCA1 normally suppresses the expression of basal-
like-related genes, which could provide an explanation for
“BRCAness” of basal-like sporadic cancers [23].
The molecular similarity between basal-like sporadic
breast cancers with BRCA-related cancers has raised the
possibility and excitement that PARP inhibitors could be
eﬀective in this patient population. BRCA1/2 is important
for homologous DNA repair. In the background of BRCA
deﬁciency,DNAdamagerepairreliesonalternativepathways
such as base excision repair pathway provided by PARP,International Journal of Breast Cancer 3
therefore inhibition of PARP would lead to accumulation of
unrepaired DNA damage and cell death. This synthetic lethal
approach has been shown to be eﬀective in BRCA-related
cancers in both preclinical and clinical settings [24–26]. The
eﬀectivenessofPARPinhibitorsinTNBC,ontheotherhand,
is not as clear. A recently published phase III trial of Iniparib
in patients with TNBC did not yield positive results [27].
HoweverIniparib,whichwasoriginallythoughttobeaPARP
inhibitor, turnedouttohave amorecomplicatedmechanism
of action unrelated to PARP so the results of this study
may not be applicable to bona ﬁde PARP inhibitors. The
question also remains as to how to best identify patients who
may beneﬁt from these agents. In the absence of a robust
biomarker predictor of treatment response, trials of PARP
inhibitors in TNBC are being conducted in all comers rather
than a deﬁned molecular subtype.
2.2. Claudin-Low Subtype. Claudin-low is the latest subtype
being identiﬁed by gene expression proﬁling studies [28]. It
is characterized by the lack of expression of claudin proteins,
which are important components of tight junctions that
seal the potential space between adjacent epithelial cells,
and epithelial cell adhesion molecules E-cadherin, EpCAM,
and mucin-1 [15]. Claudin-low tumors are typically triple
negative (61–71%), and conversely 25 to 39% of triple
negative breast cancers are of the claudin-low subtype [15].
This subtype diﬀers from the basal-like tumors, however,
due to inconsistent expression of basal keratins and a
signiﬁcantly lower expression of proliferation genes [15].
They also have low expression of luminal markers, high
expression of epithelial-to-mesenchymal transition (EMT)
markers, and cancer stem-cell-like features. The expression
of EMT markers is especially important in this group
since it has been associated with resistance to therapy and
higher metastatic potential [29, 30]. Claudin-low subtype
accordingly was found to have a lower pathologic complete
remission (pCR) rate with neoadjuvant chemotherapy than
basal-like but higher than that of the luminal subtype
putting their prognosis in between the two [15]. The
identiﬁcation of this subtype has provided further evidence
of the broad underlying biology of TNBC and the need for
a better understanding of the underlying biology of diﬀerent
subtypes of breast cancer and their therapeutic implications.
2.3. More Subtypes? To speciﬁcally subclassify TNBC,
Lehmann et al. analyzed the gene expression proﬁle of 587
TNBC cases from 21 breast cancer databases and performed
clustering analysis. Six subtypes were identiﬁed which may
have therapeutic implications (Table 2)[ 31]. Two basal-
like subtypes, BL1 and BL2, were the most prevalent and
were so named because of their similarity to the previously
described basal-like intrinsic subtype. These tumors have
high expression of genes involved in cell cycle and cell
division such as Aurora kinase and MYC and are highly
proliferative as marked by high Ki-67 nuclear staining
(BL1+BL2: 70% versus other subtypes: 42%). These results
suggest that chemotherapies that target cell division and
mitosis, such as taxanes, would be most applicable in this
Table 2: Six subtypes of triple negative breast cancer based on gene
expression proﬁling.
Subtype Gene expression proﬁle
Basal-like 1 (BL-1)
High in the expression of genes
involved in cell cycle progression,
cell division, and DNA damage
response pathways.
Basal-like 2 (BL-2)
High in the expression of genes
involved in cell cycle progression,
cell division, and growth factor
signaling.
Immunomodulatory (IM)
High in the expression of genes
involved in immune processes
and cell signaling.
Mesenchymal (M)
High in the expression of genes
involved in motility and extracel-
lular matrix.
Mesenchymal stem-like (MSL)
High in the expression of genes
involved in motility, extracellular
matrix, and growth factor signal-
ing; consistent with claudin-low
Intrinsic subtype.
Luminal androgen receptor
(LAR)
High in the expression of genes
involved in hormonally regulated
pathways.
class. Indeed, BL1 and BL2 subtypes were associated with
a signiﬁcantly higher rate of pCR (63%; P = 0.042) with
taxane-based therapies as compared to mesenchymal-like
(31%) or luminal androgen receptor (14%) subtypes [32].
In addition, elevated expression of DNA damage response
pathway genes such as CHEK1 and RAD51 were present in
the BL1 subtype, and representative cell lines were found to
be preferentially responsive to cisplatin which induces DNA
damage [31].
A third subtype, immunomodulatory (IM), was found
to be enriched in genes involved in immune processes.
These include immune transduction pathways (NFKB, TNF,
JAK), cytokine signaling such as IL-2 pathway, and antigen
processing, among others. This subtype may represent
medullary breast cancer, a subtype of TNBC that has a good
prognosis, based on a similar expression proﬁle reported in
another study [33].
Mesenchymal (M) and mesenchymal stemlike (MSL)
subtypes were characterized by expression of cell motility
genes and proteins of the extracellular matrix. The MSL
subtype displayed low expression of claudins 3, 4, and 7,
consistent with the claudin-low subtype of breast cancer
as previously discussed. MSL subtype also expressed genes
involved in growth factor signaling such as EGFR and
PDGFR pointing to possible therapeutic options in this
subtype. Cell line models of M and MSL responded to
inhibitors of PI3K/mTOR or Src.
Thesixthsubtype,luminalandrogenreceptor(LAR),was
found to be enriched in genes involved in steroid synthesis
and androgen metabolism. It has been reported previously
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the endocrine pathway despite being negative for ER and
PR [34]. This was replicated in the study by Lehmann et
al. in that a distinct subtype of TNBC, LAR subtype, was
identiﬁed that has high expressions of hormonal related
genes.AndrogenreceptormRNAwasexpressedatanaverage
of 9-fold higher level in this subtype than all the other
subtypes [31]. Interestingly, LAR subtype belongs to either
luminal A or luminal B intrinsic subtype despite being
negative for ER expression. The ﬁnding of LAR subtype
presents an exciting venue for endocrine treatment for at
least a proportion of TNBC patients.
2.4. Subclassiﬁcation of ER Breast Cancer Based on Kinase
Gene Expression. In an attempt to identity kinase targets,
Speers et al. investigated global kinase gene expression
pattern and identiﬁed 52 kinases that are diﬀerentially
expressed between ER-positive and ER-negative tumors [35].
The authors were able to further classify ER negative cancers
into four types based on the expression of these kinases. One
subtype was deﬁned by the expression of cell cycle control
kinases such as AK2, TTK, and CHK1. The second expressed
kinases in the S6 pathway. Third subtype was deﬁned by
kinases involved in modulating the immune system such as
LYN, IRAK1 and the fourth subtype deﬁned by expression of
MAPKs. Some of these tumors overexpressed HER-2 so this
classiﬁcation cannot be used speciﬁcally for TNBC, but these
kinase-based subtypes may have therapeutic implications in
targeting a particular pathway in TNBC.
3. Whole Genome Sequencing
The ﬁrst comprehensive genomic analysis of a basal-like
breast cancer was performed by using massively parallel
sequencing technology and was published in 2010 [36]. The
genome of the primary breast tumor obtained at initial
diagnosis was compared with a brain metastasis developed
at recurrence and a xenograft generated from the primary
breast tumor in an immunodeﬁcient mouse. Fifty novel
somatic point mutations and small indels as well as 28 large
deletions, 6 inversions, and 7 translocations were identiﬁed,
including mutations in TP53, JAK2,a n dMAP3K8, among
others. There was a wider range of mutation frequencies
in the primary tumor compared to the brain metastasis
and the xenograft, suggesting the existence of genetically
heterogeneous tumor cell populations in the primary breast
tumor that underwent clonal selection during the metastasis
process and the generation of xenograft. Overall this basal-
like breast cancer proved to possess an impressively complex
genome. Compared to the genome of the two acute myeloid
leukemia (AML) cases that were recently published, this
basal-like cancer genome had 3- to 4-fold more single
nucleotide variations (SNVs) [37, 38]. More genomic studies
like this, however, are needed to create a genetic landscape
of TNBC to guide therapeutics development. Importantly, as
moregenomicdataisbeinggenerated,asigniﬁcantchallenge
remains to diﬀerentiate “driver mutations” from “carrier
mutations.” Individualized treatment would not be possible
before we fully understand the biology of these genetic
abnormalities.
4. PotentialTherapeutic Targets for TNBC
4.1. SRC Inhibition. Src is a nonreceptor tyrosine kinase
involved in cell adhesion and motility [39]. In preclinical
studies, TNBC cell lines showed the highest sensitivity to
dasatinib, a small molecule kinase inhibitor of Src, Abl,
and KIT [31, 40]. Clinical studies have been disappointing
however. A phase II trial of single-agent dasatinib in patients
with advanced TNBC (CA180059) was reported in an
abstract form. Dasatinib was found to have modest single-
agent activity in these unselected TNBC patients with partial
response in 5% and disease control rate in around 10% of 44
treatedpatients[41].Asmallerstudyusingsingle-agentsara-
catinib, also a Src inhibitor, on nine ER/PR negative patients,
failed to provide positive results [42]. A speciﬁc subtype of
TNBC with Src dependence likely needs to be targeted to
provide a beneﬁt from this class of medications. Preclinical
work indicates that the mesenchymal-like subtypes are more
sensitive to Src inhibitors [31]. Mesenchymal-like subtypes
are enriched in cell motility pathways, and Src is known to
play an important role in cell migration likely explaining
their sensitivity to this class of drugs.
4.2. PARP Inhibition. As mentioned earlier, PARP inhibitors
have been an area of enthusiastic research in recent years
for the treatment of TNBCs given their similarity to BRCA-
related breast cancers. Promising results were found in a
phaseIItrialofIniparibinTNBC[38].Butasmentioned,the
beneﬁts were not conﬁrmed in the subsequent phase III trial
[27]. Given that the mechanism of action of Iniparib is now
questioned and it is likely not a PARP inhibitor as originally
thought, it is unclear what the implications of this study
are for true PARP inhibitors. The PARP inhibitor Olaparib
(AZD2281), which has been shown to be safe and eﬀective
in BRCA-related cancers, as well as other PARP inhibitors
is currently being tested in clinical trials of TNBCs [26].
The results of these studies are eagerly awaited. Given the
similarity of BRCA-related tumors and basal-like subtype,
targetingthissubtypeofTNBCmayprovidethemostbeneﬁt
from these medications.
4.3. Androgen Receptor Inhibition. An interesting target that
is currently under investigation is the androgen receptor
(AR). As mentioned earlier, despite being negative for ER
and PR, some TNBCs are positive for downstream targets of
the endocrine pathway such as the androgen receptor. These
cancers are likely concentrated in the LAR subtype of TNBC
describedbyLehmannetal.[31]andcouldbestilldependent
on an endocrine therapy responsive pathway. Although
there have been no studies targeting this particular subtype
with an AR inhibitor, a phase II trial (NCT00468715) is
currently ongoing evaluating bicalutamide, a commonly
used androgen receptor antagonist, in patients with ER/PR-
negative breast cancer. If eﬀective, this pathway has the
potential to provide a nontoxic and targeted treatment
strategy in this subtype of TNBC.
4.4. Targeting Epigenetics. T h e r ei sevi d e n c eo fg e n es i l e n c i n g
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acetylation [22]. In a recently published abstract on the ﬁrst
whole genome methylation analysis, TNBCs were indeed
found to have a distinct methylation pattern from hormone
receptor positive breast cancers [43]. Therefore it was
hypothesized that epigenetic silencing may be involved in the
lack of hormone receptors in TNBCs and demethylating or
deacetylating agents could possibly reactivate genes involved
intheendocrinepathwayandsubsequentlyrestoresensitivity
to endocrine therapy in these TNBCs. One study published
in abstract form showed reexpression of ER and PR in
TNBC after treatment with the combination of LBH589,
a histone deacetylase inhibitor, and decitabine, a known
hypomethylating agent [44]. There is another ongoing
trial using single-agent decitabine in patients with TNBC
followed by examination for ER expression and treatment
with Tamoxifen (NCT01194908). It is not clear whether
beneﬁt from epigenetic manipulation would apply to all
TNBCs or a speciﬁc subtype since gene methylation analysis
was not tested in the published subtyping analysis.
4.5. EGFR Inhibition. Overexpression of EGFR is common
in patients with TNBC and is seen in up to 60% of basal-
like breast cancers [16]. It is associated with lower response
to chemotherapy and poor overall survival [16]. As stated
above, BL-2 and MSL subtypes of TNBC have been found to
have higher expression of EGFR pathway genes. Trials have
not targeted these speciﬁc subtypes with EGFR inhibition,
and results have been disappointing in several published
abstracts [45, 46]. In a study of 102 patients with TNBC,
patients were randomized to weekly cetuximab plus or
minus carboplatin at AUC of 2. Patients who received the
combination therapy with carboplatin had a better response
rate (18% versus 6%) and clinical beneﬁt (PR or SD > 6mo)
of 27% versus 10% [45]. A second study tested carboplatin
and irinotecan plus or minus cetuximab. Despite a higher
response rate in the cetuximab-containing regimen (49%
versus 30%), PFS was similar between the two groups (5.1
months versus 4.7 months) [46]. Activation of downstream
EGFR targets, such as PI3K, may be responsible for limiting
responses to EGFR directed therapy [47].
4.6. PI3K Pathway Inhibition. Phosphatidylinositol 3-kinase
(PI3K), which is downstream of growth factor receptor
signaling pathway, plays an important role in cell survival
and proliferation and has been shown to be activated in a
subsetofTNBC,duetoPTENlossorlesscommonlyPIK3CA
mutation [48, 49]. Low PTEN expression was present in
more than 60% of TNBC tumors in one study [48]. Since
loss of PTEN is associated with increased activation of
downstream Akt and predicts response to PI3K pathway
inhibitors in preclinical models [50, 51], inhibitors of PI3K
pathways could potentially have therapeutic eﬃcacy in a
subset of TNBC. For example, NVP-BEZ235, a PI3kinase
inhibitor, has shown signiﬁcant antitumor eﬀect in the
mesenchymal-like subtype of TNBCs, which are known to
have higher expression of genes involved in EGFR pathway
[31]. Clinical trials of PI3K pathway inhibitors are needed to
conﬁrm the preclinical ﬁndings.
Table 3: Potential Therapeutic Strategies and agent examples for
TNBC.
Potential therapeutic strategies Agent examples
Src inhibition
Dasatinib;
Saracatanib
PARP inhibition
Olaparib;
ABT-888
Androgen receptor inhibition Bicalutamide
Targeting epigenetics
Decitabine
LBH589
EGFR pathway inhibition Cetuximab
PI3K pathway inhibition NVP-BEZ235;
Everolimus
5. Conclusions
Chemotherapy-resistant triple negative breast cancer re-
mains a major cause of mortality and currently lacks any
proven targeted therapy. The search for new therapeutic
targets is complicated by the tremendous complexity of
this disease, as demonstrated by the recent report of the
ﬁrst completed genome of a basal-like breast cancer. At
the level of gene expression, the TNBC group also is
actually comprised of distinct subtypes with very diﬀerent
biological signatures. All these subtypes would beneﬁt from
comprehensive analysis at the genomic, epigenomic, and
proteomic levels and the results of the cancer genome atlas
project are awaited with great interest.
There were more than 120 ongoing trials focusing on
TNBC at the time of writing of this paper per clinical-
trials.gov. As stated above, potential targeted therapy can
be applied to TNBC depending on the subtype (Table 3).
However, most of the current trials are conducted in
otherwise unselected patients and not directed by predictive
biomarkers or mechanistic hypotheses. If this relatively large
number of trials does not produce a breakthrough, we
must rethink our investigational approach for this highly
heterogeneous group of breast cancers. The development
of “genome-ﬁrst approaches” where patients are stratiﬁed
upfront and prospectively placed into clinical trials designed
to address the therapeutic hypotheses generated by analysis
of individual tumor proﬁles is surely the most logical
approach to consider.
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